The Clinical Development Accelerator

Concept

Eclipse is an accelerator programme with a specific focus on assisting biopharmaceutical therapeutic companies generate first-in-human data as expeditiously as possible (the “Accelerator”). The Accelerator will be supported by ALSA Ventures I SCSp, a Europe focussed therapeutics venture capital fund and ICON Plc, a global leader in clinical drug development services.
‍
Companies accepted into the Eclipse programme will be awarded funding support of up to $5M by ALSA Ventures I SCSp in return for equity to enable development of key asset(s) to generate first in human data.
‍
The programme will accept applications from eligible companies 4 times a year, and expects to make an award on a quarterly basis.

Benefits and rules

Companies accepted into the programme will receive funding support to enable development acceleration to the key milestone of first-in-human clinical data. In this endeavour, highly specific consulting, product development planning, project management and study conduct services will be provided by world class experts and service providers.
‍
Each award will encompass working closely with management teams to develop a bespoke programme designed specifically around generating high quality data at competitive rates, aiming at achieving faster than industry average timelines for data generation.
‍
In addition, companies accepted into the programme will benefit from access to key expertise from experienced industry professionals, to assist with later stage end-to-end product development planning from early clinical to commercialisation and market access.In addition, companies accepted into the programme will benefit from access to key expertise from Eclipse Founding Members, to assist with later stage end-to-end product development planning from early clinical to commercialisation and market access.

How does it work?

• Applications will be accepted on a quarterly basis with a submission deadline of 45 days prior to the end of each quarter.
• Applications may be submitted online here (www.alsaventures.com/eclipse-application)
• There will be a two step assessment process. Assessments will be merit based taking into account applicants’ business plans, stage of asset development, and likelihood of readiness for first in human clinical trial within 12 months of award.
• The first assessment step will involve review and approval by a joint steering committee made up of Eclipse Founding Members, ALSA Ventures and ICON Clinical Research.
• The second and final step will require approval of ALSA Ventures I SCSp Investment Committee.
• Companies accepted into the programme will be notified within 10 days of the end of the quarter after which they’ve applied.